Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.54 USD | -2.71% | +5.75% | +11.70% |
03-18 | Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer | MT |
03-18 | Fulcrum Therapeutics, Inc. Announces Executive Changes | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.70% | 482M | D+ | ||
+21.74% | 46.81B | B- | ||
-0.97% | 41.37B | B | ||
+47.07% | 41.29B | A | ||
-3.52% | 28.87B | C | ||
+11.12% | 26.06B | B- | ||
-19.37% | 19.13B | B | ||
+31.18% | 12.39B | C+ | ||
-0.04% | 12.08B | C+ | ||
+0.39% | 11.96B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FULC Stock
- Ratings Fulcrum Therapeutics, Inc.